Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients

Purpose: We have shown previously that tumor infiltration by FOXP3+ regulatory T cells (Treg) is associated with increased relapse and shorter survival of patients with both in situ and invasive breast cancer. Because estrogen regulates Treg numbers in mice and promotes the proliferation of human Tregs, we hypothesized that blocking estrogen receptor-α signaling would abrogate Tregs and be associated with response to hormonal therapy and increased survival. Experimental Design: FOXP3+ Tregs were quantified in tumor samples collected at baseline by incisional biopsy and after 6 months at definitive surgery in 83 elderly breast cancer patients (T2-4 N0-1) enrolled in a randomized phase II trial based on 6 months of primary letrozole (2.5 mg/d) or 6 months of letrozole plus oral “metronomic” cyclophosphamide (50 mg/d). Results: Treg number ranged from 0 to 380 (median, 30) before treatment and from 0 to 300 (median, 8) after treatment. There was a significant reduction in Tregs in letrozole and letrozole-cyclophosphamide patients (P < 0.0001 and P < 0.002, respectively) after treatment. Treg number at residual histology was inversely related with response (P < 0.03 and P = 0.50, respectively) and a greater Treg reduction was observed in responding patients (P < 0.03). Conclusion: This study suggests that aromatase inhibitors may have an indirect antitumor mechanism of action through reducing Tregs in breast tumors and may be of use in estrogen receptor-α-negative tumors in combination with immunotherapy approaches.

[1]  本吉 康英.  Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide , 2008 .

[2]  Christophe Benoist,et al.  Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. , 2007, Immunity.

[3]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Jooss,et al.  Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy , 2006, Clinical Cancer Research.

[5]  Manuela Milani,et al.  Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer , 2006, Clinical Cancer Research.

[6]  A. Vandenbark,et al.  Estrogen‐mediated immunomodulation involves reduced activation of effector T cells, potentiation of treg cells, and enhanced expression of the PD‐1 costimulatory pathway , 2006, Journal of neuroscience research.

[7]  S. Fox,et al.  Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Shailesh Singh,et al.  Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression , 2006, BMC Cancer.

[9]  K. Eguchi,et al.  Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. , 2006, Oncology reports.

[10]  Y. Rosenstein,et al.  Oestradiol potentiates the suppressive function of human CD4+ CD25+ regulatory T cells by promoting their proliferation , 2006, Immunology.

[11]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[12]  M. Sitkovsky,et al.  Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors , 2005, Nature Reviews Immunology.

[13]  M. Huang,et al.  Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. , 2005, Cancer research.

[14]  J. Schlom,et al.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.

[15]  S. Ziegler,et al.  FOXP3 acts as a rheostat of the immune response , 2005, Immunological reviews.

[16]  R. Epstein.  The CXCL12–CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies , 2004, Nature Reviews Cancer.

[17]  J. Body,et al.  Ibandronate reduces skeletal morbidity in patients with breast cancer. , 2004, Seminars in oncology.

[18]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[19]  R. DuBois,et al.  Cyclooxygenase-2: a potential target in breast cancer. , 2004, Seminars in oncology.

[20]  S. Saccani,et al.  Regulation of the Chemokine Receptor CXCR4 by Hypoxia , 2003, The Journal of experimental medicine.

[21]  A. Barqawi,et al.  Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma , 2003, Cancer.

[22]  D. Carbone,et al.  VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. , 2003, Blood.

[23]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[25]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[26]  T. Whiteside,et al.  Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  C. June,et al.  Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.

[28]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[29]  M. Brizzi,et al.  p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  M. Brizzi,et al.  p 53 but not bcl-2 Immunostaining Is Predictive of Poor Clinical Complete Response to Primary Chemotherapy in Breast Cancer Patients 1 , 2000 .

[31]  D. Mullins,et al.  Tumor‐induced immune dysfunction: the macrophage connection , 1998, Journal of leukocyte biology.

[32]  M. Awwad,et al.  Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. , 1990, Immunology.